MannKind Corporation (MNKD) has a MoatMap StockRank of 21/100 based on Quality (46/100), Value (41/100), and Momentum (24/100) factor scores. The current signal is SELL. MannKind Corporation is a healthcare (biotech/pharma) company. Similar to Arcus Biosciences, it likely faces high R&D costs, binary clinical trial risks, and an uncertain path to sustained profitability. These characteristics are antithetical to the fund's philosophy of investing in 'quality compounders' with durable moats and predictable cash flows.